HLA Phenotypes and Response to Interleukin 2 in Kidney Cancer
Author Information
Author(s): C Bain, Y Merrouche, I Puisieux, J-Y Blay, S Negrier, V Bonadona, C Lasset, F Lanier, A Duc, L Gebuhrer, T Philip, M C Favrot
Primary Institution: Centre Leon Berard
Hypothesis
Is there a correlation between HLA phenotypes and clinical response to interleukin 2 in patients with metastatic renal cell carcinoma?
Conclusion
The study found that certain HLA phenotypes, particularly A32, are associated with a better clinical response to interleukin 2 treatment in metastatic renal cell carcinoma patients.
Supporting Evidence
- HLA-A32 was associated with a clinical response (p=0.025).
- The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (p=0.008).
- 61% of responder patients expressed HLA-A3 and/or A32 compared to 28% of non-responders.
Takeaway
This study looked at how certain genes in our body might help some kidney cancer patients respond better to a treatment called interleukin 2.
Methodology
HLA phenotyping was performed on peripheral blood mononuclear cells from patients treated with interleukin 2, and the results were compared to a control group.
Limitations
The study had a small sample size, which limits the ability to draw definitive conclusions.
Participant Demographics
Patients were of European ancestry, with a median age of 55 years.
Statistical Information
P-Value
0.025
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website